At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin, cyclophosphamide, and 2 other interventions for Peripheral T-cell Lymphoma. Completed, enrolled 82 participants across 63 sites in 5 countries.
Detailed Summary
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
Study Details
Timeline
Interventions
1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
100 mg daily administered orally on Days 1-5 of each cycle